Market research reports, consulting: Global Market Insights Inc.

Home > Healthcare > Pharmaceuticals > Drug Delivery > inhalable drugs market

Inhalable Drugs Market Share

Report ID: GMI10744 Published Date: August 2024Report Format: PDF
Download Free Sample
Summary
Table of Content

Inhalable Drugs Market Share

The inhalable drugs sector is competitive in nature, with a mix of major global and smaller to medium-sized companies competing for market share. A pivotal aspect of market strategy involves the continual introduction of innovative products leveraging diverse technologies. Notably, prominent industry players command considerable influence in this dynamic landscape, often driving forward advancements through substantial investments in research and development. Additionally, strategic alliances, acquisitions, and mergers are instrumental in fortifying market positions and expanding global footprint amidst evolving regulatory landscapes.

Inhalable Drugs Market Companies

Some of the eminent market participants operating in the inhalable drugs industry include:

  • AstraZeneca Plc                            
  • C.H. Boehringer Sohn AG & Co. KG.                              
  • CHIESI Farmaceutici S.p.A.                     
  • Cipla Limited                      
  • GSK plc                             
  • MannKind Corporation                             
  • Merck & Co., Inc.                         
  • Mundipharma International.                    
  • Novartis AG                       
  • Pfizer Inc.                          
  • PULMATRIX, INC.                         
  • Philip Morris International Inc.                           
  • Sanofi                     
  • Teva Pharmaceutical Industries Ltd.                              
  • Viatris,Inc.
Author: Mariam Faizullabhoy, Gauri Wani
Frequently Asked Question(FAQ) :

Who are the leading inhalable drugs industry players?+

AstraZeneca Plc, C.H. Boehringer Sohn AG & Co. KG., CHIESI Farmaceutici S.p.A., Cipla Limited, GSK plc, MannKind Corporation, Merck & Co., Inc., Mundipharma International., Novartis AG, and Pfizer Inc., among others.

How big is the U.S. inhalable drugs industry?+

U.S. inhalable drugs market is projected to reach USD 21.8 billion by 2032 due to increasing pharmaceutical and biotechnological innovation and rising investment in R&D.

Why is the demand for inhalable drugs rising in respiratory diseases?+

The respiratory diseases segment in the market recorded USD 24.2 billion in 2023 due to targeted lung delivery, rapid onset, and improving efficacy.

What is the size of the inhalable drugs market?+

Global inhalable drugs industry was valued at USD 33.4 billion in 2023 and is anticipated to register 6.8% CAGR between 2024 and 2032 due to the increasing prevalence of respiratory diseases and advancements in inhalation technology.

Inhalable Drugs Market Scope

Related Reports

Buy Now

Premium Report Details

Download Free Sample